Ibogaine

Ibogaine is the main alkaloid of iboga (Tabernanthe iboga), a shrub of equatorial Africa. It is an atypical oneirogen, outside the classical serotonergic paradigm: it does not act mainly on 5-HT2A. Where most psychedelics target a narrow site, ibogaine is a promiscuous molecule that touches a wide range of systems, and its typical experience is neither the entity-peopled geometry of DMT nor the dissolution of reality of salvia, but a long waking dream: a panoramic, almost judicial autobiographical review. Its recent clinical rehabilitation rests on an anti-addiction use and on effects on trauma, at the cost of a real cardiotoxicity that makes it one of the most physically dangerous psychoactives.

Pharmacology

Ibogaine stands out for a broad profile, sometimes called dirty, the opposite of the purity of a selective ligand. It acts notably as:

• an NMDA receptor antagonist (a dissociative component);
• a ligand of the kappa and mu opioid receptors;
• an agent on the sigma and nicotinic receptors;
• a modulator of the serotonin transporter (SERT);
• an inducer of GDNF (glial cell line-derived neurotrophic factor), central to the anti-addiction and pro-plasticity hypothesis.

Its main metabolite, noribogaine, is active and long-lived: it stretches the effects and the cardiac risk well beyond the moment of dosing. This receptor promiscuity contrasts point by point with salvia's salvinorin A, a kappa-opioid agonist of an almost insolent selectivity. Two opposite ways of leaving 5-HT2A behind: the purity of a single receptor on one side, multi-target dispersion on the other.

Time course and phenomenology

Ibogaine inverts salvia's time course point by point: not 5 to 15 minutes, but an oneiric phase of several hours, for a total running over 24 to 36 hours. It is an oneirogen: not a dissolution of reality, but a panoramic waking dream. The central motif is the autobiographical review, the almost cinematic procession of one's own life that the subject is summoned to watch and, often, to judge. Structurally, it is neither salvia's object-substitution (becoming a chair, a pane of glass) nor DMT's entity-geometry: something narrative, mnesic, almost judicial.

Three regimes on the self-model

Set side by side, three broad families of psychoactives act on the self-model in distinct ways, which undoes the idea of a generic psychedelic effect:

• the classical serotonergics (LSD, psilocybin, DMT) relax high-level priors and loosen the predictive hierarchy, hence the plasticity and the feeling of liberation (the REBUS frame);
• salvia relaxes nothing: it substitutes an alien prior with maximal precision, rewriting the model with no error signal;
• ibogaine would rather replay then reconsolidate the autobiographical archive. Its forced life-review looks less like an anarchy of the hierarchy than like a directed, sustained replay of episodic memories, close to a window of memory reconsolidation, consistent with the induction of GDNF and the pro-plasticity effect.

These parallels with the predictive brain remain conjectures: applying the REBUS frame beyond 5-HT2A has not been properly established. But they economically account for the gap in valence and the gap in liberation between these families (see the Bayesian brain page).

Iboga, Bwiti and the redemptive narrative

Ibogaine has what salvia never had: a supporting frame, and even two. The ethnographic anchoring first, the Gabonese Bwiti, where the root of Tabernanthe iboga is the initiatory sacrament par excellence: symbolic death, encounter with the ancestors, rebirth. Then the founding Western narrative, which is a narrative of healing. In 1962, Howard Lotsof, a 19-year-old heroin addict, takes ibogaine and finds his withdrawal syndrome and his craving gone. From there the whole cultural career of ibogaine is built as the anti-salvia: the terrible descent that heals, the ordeal one comes out of repaired. Its darkness is not a deterrent, it is recoded as a price of entry, as a therapeutic ordeal.

Clinical rehabilitation

Ibogaine is in full institutional rehabilitation. Nolan Williams's Stanford study (Nature Medicine, 2024) followed 30 special-forces veterans with traumatic brain injuries, treated with ibogaine co-administered with magnesium. The results are striking: the mean disability score drops from about 30 (mild to moderate disability) to about 5 one month later, with mean reductions of 88 % in post-traumatic stress symptoms, 87 % in depression and 81 % in anxiety. The decisive detail is the magnesium: ibogaine having been associated with fatal arrhythmias, its co-administration aims to blunt the cardiac risk. The whole modern programme thus consists, literally, in neutralising the deadly substrate in order to deliver the redemptive payload. Politically, in 2025 Texas voted fifty million dollars of public funds for ibogaine research (SB 2308 and HB 3717), toward FDA-approved clinical trials: the largest psychedelic research initiative ever funded by a state, led by UTHealth Houston and UTMB, with other states joining the consortium.

Harm reduction

Ibogaine is one of the rare psychoactives whose danger is first somatic and potentially lethal, not psychological or theatrical. It is cardiotoxic: it blocks the hERG potassium channels, prolongs the QT interval and can trigger a fatal arrhythmia (torsades de pointes). The risk is worsened by the very profile of the population that seeks it, often in opioid withdrawal and depleted in electrolytes. Deaths are documented, including in the clinic. Where salvia alarms the witness (the body that staggers and falls), ibogaine puts on no show: it can stop the heart in silence. Serious protocols require a prior cardiac work-up, an electrocardiogram and continuous monitoring, electrolyte correction and the co-administration of magnesium. Combining it with other QT-prolonging substances, with opioids and with stimulants is to be avoided. Use outside a medical setting, without monitoring, is at very high risk.

Sources

• Ritual use of iboga (Tabernanthe iboga) in the Bwiti (Gabon): symbolic death, ancestors, rebirth.
• Howard Lotsof and the discovery of ibogaine's anti-addiction effect (1962) (patent filed in 1985).
• Cherian, Williams et al. (2024), Magnesium-ibogaine therapy in veterans with traumatic brain injuries, Nature Medicine (Cherian KN first author; N.R. Williams senior author).
• J.I. Lissemore et al. (2025), neurophysiological effects of magnesium-ibogaine therapy, Nature Mental Health.
• Texas SB 2308 and HB 3717 (2025): public funding for research, UTHealth Houston and UTMB consortium.
• Literature on ibogaine cardiotoxicity (hERG blockade, QT prolongation) and on GDNF induction (the anti-addiction and neuroplasticity hypothesis).